Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis

Published:2016-06-14 Issue:28 Volume:7 Page:44545-44557
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Zhu Chenjing¹,Ma Xuelei¹,Hu Yuanyuan²,Guo Linghong²,Chen Bo³,Shen Kai¹,Xiao Yue²

Affiliation:

1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, PR China

2. West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, PR China

3. Department of Oncology, The First People's Hospital of Chengdu City, Chengdu 610041, PR China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ag(I)-NHC/TBHP promoted aqueous synthesis of some new quinoline-aromatic amides; Anti-proliferative, Anti-VEGFR-2 and Molecular docking studies;Journal of Molecular Structure;2024-10

2. Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database;British Journal of Clinical Pharmacology;2024-09-02

3. Reserpine, a novel N6-methyladenosine regulator, reverses Lenvatinib resistance in hepatocellular carcinoma;Phytomedicine;2024-09

4. Nonadherence to oral cancer chemotherapy in hepatocellular carcinoma: prevalence and predictive factors in Vietnam;BMC Cancer;2024-07-15

5. Tyrosine Kinase Inhibitor Lenvatinib Causes Cardiotoxicity by Inducing Endoplasmic Reticulum Stress and Apoptosis through Activating ATF6, IRE1α and PERK Signaling Pathways;Recent Patents on Anti-Cancer Drug Discovery;2024-07-11